The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Seminar PH2 – Cancer Therapy: review of the present and a look to the future
Affiliation
Uppsala University Hospital
Country
Sweden
1. Current Status, Position
Dr. Gullbo (MD PhD) is Senior Consultant in oncology, with an emphasis on breast cancer. He is also an associate professor in academic research focused on research and development of new anticancer drugs.
2. Education
- 1996: MSc in Pharmacy, Faculty of Pharmacy, Uppsala University.
- 2002: Medical Degree, Faculty of Medicine, Uppsala University.
- 2003: PhD in Clinical Pharmacology, Institution of Medical Sciences, Uppsala University (Thesis: Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy).
- 2009: Associate Professor in experimental Clinical Pharmacology.
- 2012: Consultant/Specialist in Clinical Pharmacology, 2011 – Consultant/Specialist in Oncology.
3. Research Area
Dr Gullbo´s research is focused on preclinical development and evaluation of new cancer therapies. His research has been based on rational synthesis, traditional screens of chemical libraries as well as investigations of natural products. Three compounds are currently being investigated in clinical trials. As a clinician, Dr Gullbo has participated in numerous clinical trials and has special interest in breast cancer treatment.
4. Conflict of interest: none